Other top stories

A Third of Former NFL Players Believe They Have CTE

October 3, 2024

Xanomeline-Trospium Shows Promise in Schizophrenia with Fewer Side Effects

October 3, 2024

Evaluating Pooled Data from the EMERGENT Study Programs

October 3, 2024

Study Links Conversion Therapy to Increased PTSD, Other Issues

October 2, 2024

Study Highlights Increased Mortality Risks in Difficult-to-Treat Depression

October 1, 2024

Study Finds Brain Network That Could Protect Against PTSD

September 30, 2024

Other stories

Weekly Mind Reader: The Price of Social Isolation

September 27, 2024

FDA Approves First New Schizophrenia Drug in Years

September 27, 2024

Study Finds High COVID Vaccination Rates Among Mentally Ill, But Gaps Persist

September 26, 2024

Research Reveals Mental Health Effects of Community Disasters, Highlighting PTSD

September 25, 2024

Comorbidity Compounds Disease Activity in MS Patients

September 24, 2024

IPT Could Be a Better Alternative to Exposure-Based PTSD Therapy

September 23, 2024

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe